As of July 17, 2026, a new front has opened in gabapentin litigation that this article doesn’t yet cover: emerging lawsuits over dementia and cognitive decline. These claims are built on a July 2025 observational study in Regional Anesthesia & Pain Medicine, which found that patients receiving six or more gabapentin prescriptions for back pain had a 29% higher risk of developing dementia and roughly 85–89% higher risk of mild cognitive impairment, with adults aged 18–64 more than twice as likely to be affected. As of June 2026, no class action or MDL has been established specifically for dementia claims; law firms are still in the early stage of individually investigating and filing these cases, separate from the kidney, suicide-risk, and addiction claims already outlined above.
Last updated: July 2026
The gabapentin class action lawsuit payout per person in 2026 could range from $5,000 to over $250,000, depending on the type and severity of injury suffered. These cases center on claims that Pfizer and its subsidiaries promoted gabapentin for uses the FDA never approved, exposing millions of patients to serious health risks.
If you took gabapentin and experienced kidney damage, suicidal thoughts, or dependency issues, you may qualify for compensation. This article breaks down expected payout tiers, who’s eligible, how to file, and what’s happening in court right now.
Here’s one fact worth knowing: Pfizer already paid $430 million to the DOJ back in 2004 for illegal gabapentin marketing. The current wave of lawsuits could dwarf that figure.
You’ll find settlement estimates, filing deadlines, injury-specific claim details, and a clear explanation of what to expect in 2026.
Gabapentin Class Action Lawsuit Payout Per Person
The gabapentin class action lawsuit payout per person depends on three main factors: the severity of your injury, how long you took the drug, and the strength of your medical documentation. Not every claimant will receive the same amount, and that’s typical in pharmaceutical litigation.
Individual payouts in cases like this are determined by a tiered system. Think of it like an insurance claim. A fender bender pays less than a totaled car. The same logic applies here.
| Injury Tier | Estimated Payout Per Person | Typical Injuries |
|---|---|---|
| Tier 1 (Severe) | $100,000 to $250,000+ | Kidney failure, organ damage, death |
| Tier 2 (Moderate) | $25,000 to $100,000 | Suicidal ideation, hospitalization, severe dependency |
| Tier 3 (Low) | $5,000 to $25,000 | Mild side effects, short-term dependency, minor harm |
Claimants in the highest tier typically have hospital records, specialist diagnoses, and documented long-term health consequences. Those with less documentation or milder symptoms fall into lower tiers.
The per-person payout also depends on whether the case settles as a class action or as individual mass tort claims. Mass tort cases generally produce higher payouts because each case is evaluated on its own merits.
Your actual settlement check will arrive only after attorney fees, court costs, and administrative deductions. Most contingency fee agreements take 25% to 40% of your gross payout.
Gabapentin Lawsuit Settlement Amounts 2026
Gabapentin lawsuit settlement amounts in 2026 are projected based on prior pharmaceutical fraud cases and the current volume of claims being filed. No global settlement has been finalized yet, but legal analysts are watching several key indicators.
The total settlement fund, if one is established, could reach $1 billion or more based on the number of affected patients and the severity of documented injuries. Pfizer’s 2004 DOJ settlement of $430 million covered only the federal fraud component and did not compensate individual patients.
| Comparison | Total Settlement | Per-Person Range |
|---|---|---|
| Pfizer DOJ Settlement (2004) | $430 million | N/A (government only) |
| Opioid MDL Settlements | $26 billion+ | $500 to $50,000+ |
| Zantac Settlement (projected) | $1 billion+ | $10,000 to $200,000 |
| Gabapentin (2026 projected) | $1 billion+ (estimated) | $5,000 to $250,000+ |
These estimates reflect ongoing legal analysis and are not guaranteed. The actual amounts will depend on bellwether trial outcomes, the number of valid claims, and Pfizer’s willingness to negotiate.
Settlement amounts in 2026 could shift dramatically if early bellwether trials produce large jury verdicts. A single verdict exceeding $10 million for one plaintiff would pressure the manufacturer to settle the remaining cases quickly.
Keep in mind that large pharmaceutical settlements often take years to distribute. Even after a deal is reached, the claims review process adds months to the timeline.
Who Qualifies for the Gabapentin Lawsuit
You may qualify for the gabapentin lawsuit if you were prescribed gabapentin (sold as Neurontin) and suffered adverse health effects that were not adequately disclosed by the manufacturer. The key question is whether your doctor prescribed it for an off-label use that Pfizer promoted illegally.
Here are the primary qualifications:
- You took gabapentin at any point between 1994 and 2025
- You experienced documented side effects (kidney damage, dependency, suicidal thoughts, respiratory problems)
- Your prescription was for a condition not approved by the FDA (migraines, bipolar disorder, pain syndromes)
- You have medical records linking gabapentin use to your injuries
Quick Facts:
The FDA originally approved gabapentin only for epilepsy (1993) and later for postherpetic neuralgia (2002). Any prescription outside those two conditions was off-label. Pfizer aggressively pushed doctors to prescribe it for at least a dozen other conditions.
If you’re unsure whether your prescription was off-label, check your medical records. The diagnosis code on your prescription will tell you what condition your doctor was treating. If it wasn’t epilepsy or postherpetic neuralgia, your case likely qualifies.
Family members of someone who died while taking gabapentin may file a wrongful death claim as part of this litigation.
Key Takeaway: Your potential payout depends on injury severity, and you likely qualify if your gabapentin prescription was for an off-label use and caused documented harm.
Gabapentin Class Action Lawsuit Update 2026
The gabapentin class action lawsuit in 2026 is gaining serious momentum as more plaintiffs join the litigation and courts begin organizing cases for trial preparation. Several state and federal actions are now active, with attorneys filing new claims every week.
As of early 2026, no single class action has been formally certified for gabapentin injury claims. Instead, most cases are being handled through mass tort filings and individual lawsuits consolidated for pretrial purposes.
Key developments to watch in 2026:
- Bellwether trial selection: Courts are expected to choose test cases that will go to trial first, which will set the tone for settlement negotiations
- Expert witness challenges: Both sides are battling over which medical experts can testify about gabapentin’s side effects
- Document discovery: Internal Pfizer marketing documents from the late 1990s and early 2000s continue to surface, showing the scope of off-label promotion
The litigation is still in its earlier stages compared to mature pharmaceutical MDLs like opioids. But the pace is picking up. Legal observers expect 2026 to be a pivotal year for shaping the case’s direction.
One important point: the original Pfizer DOJ case revealed that sales representatives were trained to promote gabapentin for conditions like pain, anxiety, and bipolar disorder. Those internal training materials are now being used as evidence in the current lawsuits.
Gabapentin Side Effects Lawsuit
The gabapentin side effects lawsuit targets the manufacturer’s failure to warn patients and doctors about serious risks associated with the drug. Plaintiffs argue that Pfizer knew about dangerous side effects but downplayed or hid them to protect sales.
Gabapentin’s side effects range from mild to life-threatening. The lawsuits focus on the severe end of that spectrum.
| Side Effect | Severity | Lawsuit Relevance |
|---|---|---|
| Kidney damage or failure | Severe | Central claim in many lawsuits |
| Suicidal thoughts or behavior | Severe | FDA added black box warning in 2009 |
| Physical dependency and withdrawal | Moderate to Severe | Addiction claims growing rapidly |
| Respiratory depression | Severe | Fatal when combined with opioids |
| Dizziness and drowsiness | Mild | Typically not sufficient for individual claims |
| Weight gain and edema | Mild | Usually part of broader claim |
The FDA issued a safety warning in December 2019 about serious breathing difficulties in patients using gabapentin, especially those with respiratory risk factors. This warning came years after millions of patients had already been prescribed the drug.
Plaintiffs point out that Pfizer had data suggesting these risks long before the FDA acted. Internal documents show the company was aware of respiratory depression risks as early as the late 1990s.
If you experienced any severe side effect listed above while taking gabapentin, your medical records could form the basis of a strong legal claim.
Gabapentin Off-Label Marketing Lawsuit
The gabapentin off-label marketing lawsuit is the backbone of this entire litigation. Pfizer’s predecessor, Warner-Lambert (through its Parke-Davis division), ran one of the most aggressive off-label marketing campaigns in pharmaceutical history.
Between 1995 and 2004, sales teams promoted Neurontin for at least 11 conditions the FDA never approved. These included migraines, bipolar disorder, restless leg syndrome, attention deficit disorder, and various pain conditions.
Here’s what made this so damaging. Doctors relied on Pfizer’s marketing materials to make prescribing decisions. When those materials exaggerated benefits and hid risks, patients paid the price.
- Pfizer paid doctors to attend “educational seminars” that were actually sales events
- The company hired medical writers to produce ghost-written journal articles supporting off-label uses
- Internal memos showed executives were fully aware these promotions violated federal law
- Whistleblower David Franklin, a former Parke-Davis employee, helped expose the scheme
The 2004 DOJ settlement of $430 million confirmed the illegal marketing but did not compensate individual patients. That’s what the current lawsuits aim to fix.
If you were prescribed gabapentin for anything other than epilepsy or postherpetic neuralgia, the off-label marketing campaign is likely the reason. Your doctor may not have even realized they were being influenced by fraudulent promotion.
Key Takeaway: Pfizer’s illegal off-label marketing campaign is the engine driving these lawsuits, and the company already admitted wrongdoing by paying $430 million to the DOJ in 2004.
Pfizer Gabapentin Lawsuit
The Pfizer gabapentin lawsuit holds the pharmaceutical giant responsible for promoting Neurontin far beyond its FDA-approved uses. Pfizer inherited this liability when it acquired Warner-Lambert in 2000 for $90 billion, taking ownership of the entire Neurontin product line and its legal baggage.
Pfizer’s connection to the gabapentin scandal runs deep. Even after the 2004 DOJ settlement, the company continued to profit enormously from gabapentin prescriptions. At its peak, Neurontin generated $2.7 billion in annual sales, with an estimated 90% coming from off-label prescriptions.
That number is staggering. Nine out of every ten prescriptions were for conditions the drug was never proven to treat safely.
Key facts about Pfizer’s involvement:
- Warner-Lambert developed and initially marketed Neurontin
- Pfizer acquired Warner-Lambert and all associated liabilities in 2000
- Pfizer paid $430 million in criminal and civil penalties in 2004
- The company also lost a $142 million RICO verdict in a 2010 class action by health insurers
- Current lawsuits name Pfizer as the primary defendant
Pfizer has the financial resources to fight these cases for years. But the internal documents already made public are extremely damaging. Courts have repeatedly found that the company’s marketing practices were deceptive and harmful.
The current lawsuits seek compensation that the 2004 settlement never provided: direct payments to the patients who were harmed.
Gabapentin Lawsuit Eligibility Requirements
Gabapentin lawsuit eligibility requirements center on your prescription history, the injuries you suffered, and whether your use of the drug was tied to off-label marketing. You don’t need a perfect case, but you do need documentation.
Here’s a clear breakdown of what you need:
| Requirement | Details |
|---|---|
| Prescription proof | Medical records, pharmacy records, or insurance claims showing gabapentin use |
| Off-label use | Prescription for a condition other than epilepsy or postherpetic neuralgia |
| Documented injury | Medical records showing a diagnosed side effect or adverse event |
| Causation link | A doctor’s opinion or medical evidence connecting gabapentin to your injury |
| Statute of limitations | Must file within your state’s deadline (varies by state, typically 2 to 3 years from discovery of injury) |
You do not need to prove that Pfizer personally marketed the drug to your doctor. The lawsuits rely on proving that the company’s broad marketing campaign influenced the medical community as a whole.
Strong cases typically include:
- Hospital records for kidney treatment, psychiatric care, or respiratory events
- Records showing gabapentin was the only new medication when symptoms started
- A treating physician willing to confirm the drug caused or contributed to the injury
Weak cases, those with only minor side effects and no medical documentation, may still participate in a class action but will likely receive lower payouts.
How to File a Gabapentin Lawsuit
Filing a gabapentin lawsuit starts with gathering your medical records and connecting with an attorney who handles pharmaceutical litigation. The process isn’t complicated, but timing matters.
Step-by-step filing process:
- Collect your records. Get your prescription history, pharmacy receipts, and any medical records showing gabapentin-related side effects or injuries.
- Identify your injury. Know what harm you suffered. Was it kidney damage? Dependency? Suicidal thoughts? Respiratory issues? Be specific.
- Contact a pharmaceutical attorney. Look for law firms handling gabapentin or Neurontin cases. Most work on contingency, meaning you pay nothing upfront.
- Complete an intake form. Your attorney will ask detailed questions about your medical history, gabapentin use, and symptoms.
- Attorney files the complaint. Once your case is evaluated and accepted, your lawyer files a formal complaint in the appropriate court.
- Case joins the litigation. Depending on your state and the specifics, your case may be consolidated with others for pretrial proceedings.
Most attorneys offer free case evaluations. You don’t need to pay anything to find out if you qualify.
One thing to understand: filing a lawsuit doesn’t mean going to trial. The vast majority of pharmaceutical cases settle before trial. Your attorney handles nearly all of the work. Your main job is providing records and answering questions about your experience.
Gabapentin Lawsuit Filing Deadline 2026
The gabapentin lawsuit filing deadline in 2026 varies by state because each state has its own statute of limitations for personal injury and product liability claims. Missing your deadline means losing your right to sue, permanently.
| State | Statute of Limitations | Clock Starts From |
|---|---|---|
| California | 2 years | Date injury was discovered |
| Texas | 2 years | Date of injury |
| New York | 3 years | Date of injury |
| Florida | 2 years (changed from 4 in 2024) | Date injury was discovered |
| Illinois | 2 years | Date injury was discovered |
| Pennsylvania | 2 years | Date of injury |
The “discovery rule” is important here. In many states, the clock doesn’t start when you took gabapentin. It starts when you knew, or should have known, that gabapentin caused your injury. This rule extends the window for people who didn’t connect their health problems to the drug until recently.
If you’re reading this in 2026, act now. Even if your state has a 3-year window, delays in gathering records or finding an attorney can eat into that time.
Some attorneys are warning that any future global settlement could include a claims filing cutoff date. If a settlement is reached and you haven’t filed, you could be locked out even if you technically had time left under your state’s statute.
Key Takeaway: Filing deadlines vary by state and can be as short as two years from when you discovered your injury, so checking your state’s rules immediately is the smartest move you can make.
Gabapentin Kidney Damage Lawsuit
The gabapentin kidney damage lawsuit focuses on evidence that long-term gabapentin use can cause renal impairment, kidney disease, and in severe cases, kidney failure. These are some of the most high-value claims in the litigation.
Medical studies have found that gabapentin is almost entirely eliminated through the kidneys. Patients with even mild pre-existing kidney issues are at heightened risk because the drug accumulates in their system when the kidneys can’t filter it efficiently.
Kidney damage symptoms linked to gabapentin include:
- Decreased urine output or changes in urination
- Swelling in the legs, ankles, or feet (edema)
- Persistent fatigue or confusion
- Nausea and appetite loss
- Elevated creatinine levels in blood tests
Plaintiffs in kidney damage cases argue that Pfizer failed to adequately warn about renal risks, especially for patients prescribed gabapentin off-label. Many of these patients had no reason to be on the drug in the first place, which makes the kidney damage even more inexcusable.
Kidney damage claims tend to produce higher settlements because the medical costs are substantial. Dialysis treatments alone can cost $90,000 or more per year. A kidney transplant runs upwards of $400,000.
If you developed kidney problems while taking gabapentin, your nephrologist’s records will be central to your case. Blood work showing declining kidney function during the period of gabapentin use is some of the strongest evidence available.
Gabapentin Suicide Risk Lawsuit
The gabapentin suicide risk lawsuit addresses claims that the drug increases the risk of suicidal thoughts and behaviors, particularly in younger patients and those prescribed it for mood disorders. This is one of the most emotionally charged aspects of the litigation.
The FDA added a warning about suicidality to gabapentin’s label in 2009, covering all anticonvulsant drugs. But plaintiffs argue this warning came far too late. By 2009, tens of millions of patients had already taken the drug without being told about this risk.
Key facts about gabapentin and suicide risk:
- An FDA meta-analysis found that anticonvulsants, including gabapentin, doubled the risk of suicidal thoughts compared to placebo
- The risk appeared as early as one week after starting the medication
- Patients prescribed gabapentin off-label for mood disorders were particularly vulnerable
- Internal Pfizer documents suggest the company had data about psychiatric adverse events years before the FDA warning
Families who lost loved ones to suicide while they were taking gabapentin are filing wrongful death claims. These cases carry significant emotional weight in front of juries and often result in higher settlements or verdicts.
Surviving patients who experienced suicidal ideation, self-harm, or psychiatric hospitalization while on gabapentin also have strong claims. Documentation from psychiatrists, emergency room visits, or crisis intervention records strengthens these cases considerably.
The irony is hard to miss. Many patients were prescribed gabapentin off-label for anxiety or depression. The drug may have made those very conditions worse.
Gabapentin Addiction Lawsuit
The gabapentin addiction lawsuit targets claims that the drug carries a real risk of physical dependency and withdrawal, despite being marketed as a non-addictive alternative to other medications. For years, gabapentin was promoted as a safer option precisely because it wasn’t classified as a controlled substance.
That classification is changing. As of 2026, several states have reclassified gabapentin as a Schedule V controlled substance, including Kentucky, West Virginia, Virginia, Michigan, and Tennessee. These state actions reflect growing recognition that gabapentin has genuine abuse potential.
| State | Gabapentin Scheduling Status |
|---|---|
| Kentucky | Schedule V (since 2017) |
| West Virginia | Schedule V (since 2017) |
| Virginia | Schedule V (since 2019) |
| Michigan | Schedule V (since 2019) |
| Tennessee | Schedule V (since 2018) |
| Federal (DEA) | Not scheduled (as of 2026) |
Withdrawal symptoms from gabapentin can be severe. They include seizures, anxiety, insomnia, nausea, sweating, and pain. Some patients report withdrawal effects lasting weeks or months.
Plaintiffs argue that Pfizer knew gabapentin had dependency risks but deliberately marketed it as non-addictive to gain market share, especially in the pain management space where doctors were looking for opioid alternatives.
The addiction lawsuits are particularly strong when patients can show they were not warned about dependency risks and suffered significant withdrawal symptoms when trying to stop the medication.
Key Takeaway: Gabapentin’s reputation as a “non-addictive” drug is crumbling, and lawsuits targeting the manufacturer’s failure to warn about dependency risks are growing rapidly across the country.
Gabapentin MDL Status 2026
The gabapentin MDL status in 2026 is a developing situation. As of early 2026, no formal federal MDL (multidistrict litigation) has been established exclusively for gabapentin injury claims, but legal experts expect one to be created as the volume of cases increases.
An MDL works by consolidating similar federal lawsuits before one judge for pretrial proceedings. This speeds up the discovery process, avoids conflicting rulings, and creates efficiency. Think of it as putting all the cases in one courtroom to handle the paperwork, while keeping each case individual for trial purposes.
Current litigation landscape:
- Federal cases are filed in various district courts across the country
- A petition to the Judicial Panel on Multidistrict Litigation (JPML) for formal consolidation is expected in 2026
- State-level cases continue independently in jurisdictions like California, Pennsylvania, and New York
- Some gabapentin claims overlap with broader opioid-related litigation
The existing 2004 fraud case was handled in the District of Massachusetts under Judge Patti Saris. If a new MDL is created, it could be assigned to the same district given the court’s familiarity with gabapentin litigation history.
Attorneys are currently in the case-building phase. They’re gathering plaintiffs, collecting medical records, and preparing the evidence packages needed for bellwether trial selection. The formation of an MDL would be a major milestone, signaling that the litigation has reached critical mass.
Gabapentin Settlement Payout Timeline
The gabapentin settlement payout timeline in 2026 is still in its early stages. No global settlement has been reached, and payments to individual plaintiffs have not yet begun. Based on how similar pharmaceutical cases have progressed, here’s a realistic timeline.
| Phase | Estimated Timeframe | What Happens |
|---|---|---|
| Case filing and consolidation | 2024 to 2026 | Plaintiffs file, cases organized |
| Discovery and pretrial | 2026 to 2027 | Document exchange, expert reports |
| Bellwether trials | 2027 to 2028 | Test cases go to trial |
| Settlement negotiations | 2028 to 2029 | Global settlement discussions begin |
| Claims review and payout | 2029 to 2030 | Individual claims processed and paid |
This timeline is an estimate based on comparable pharmaceutical MDLs. The opioid litigation took roughly 5 to 7 years from mass filing to initial settlements. The Zantac litigation moved faster in some respects but also faced major setbacks.
Several factors could speed things up:
- A massive bellwether verdict that pressures Pfizer to settle
- A wave of state attorney general actions that add political pressure
- Pfizer deciding that a settlement is cheaper than years of litigation
Patience is required. Pharmaceutical settlements are not fast. But the size of the potential payout makes the wait worthwhile for many plaintiffs. If you file now, you’re securing your place in line for when distributions begin.
Gabapentin Class Action vs Mass Tort
A gabapentin class action and a gabapentin mass tort are two different legal structures, and the distinction affects how much money you could receive. Most gabapentin injury claims are being handled as mass tort cases, not class actions.
| Feature | Class Action | Mass Tort |
|---|---|---|
| Individual case evaluation | No (all treated equally) | Yes (each case on its own merits) |
| Payout per person | Lower (divided among all members) | Higher (based on individual damages) |
| Plaintiff involvement | Minimal | More active |
| Settlement speed | Generally faster | Generally slower |
| Who controls the case | Lead plaintiff and class counsel | Your individual attorney |
In a class action, everyone gets the same payout regardless of how badly they were hurt. In a mass tort, your payout reflects your specific injuries, medical costs, and suffering. That’s a big difference.
The gabapentin litigation currently leans toward mass tort because the injuries vary so widely from person to person. Someone with kidney failure has a fundamentally different case than someone who experienced mild dizziness.
Some portions of the litigation, like claims from health insurance companies seeking reimbursement for off-label prescriptions, have proceeded as class actions. The 2010 Kaiser Foundation Health Plan case that produced a $142 million RICO verdict was structured this way.
For individual patients, mass tort is almost always the better path. You give up some speed in exchange for a payout that actually reflects what happened to you.
Key Takeaway: Most gabapentin injury claims are mass tort cases, not class actions, which means your payout will be based on your individual injuries and medical evidence rather than a one-size-fits-all amount.
Average Gabapentin Lawsuit Settlement Amount
The average gabapentin lawsuit settlement amount in 2026 cannot be stated with certainty because no global settlement has been reached yet. However, legal experts are projecting average payouts based on the type of claims being filed and results from comparable pharmaceutical cases.
Based on current case profiles:
| Claim Type | Projected Average Settlement |
|---|---|
| Kidney failure or transplant | $150,000 to $250,000+ |
| Suicidal ideation with hospitalization | $75,000 to $200,000 |
| Severe dependency and withdrawal | $25,000 to $100,000 |
| Wrongful death | $200,000 to $500,000+ |
| Minor side effects (mild claims) | $5,000 to $20,000 |
The average across all claim types, if a settlement is reached, would likely fall in the $30,000 to $75,000 range. That average gets pulled down by the large number of lower-tier claims.
Here’s context that helps. In the opioid manufacturer settlements, per-person payouts for individual injury claims ranged from a few thousand dollars to several hundred thousand. The wide spread reflects the enormous variation in individual circumstances.
Your specific settlement will depend on:
- Quality of your medical documentation
- Severity and permanence of your injuries
- Whether your doctor prescribed gabapentin off-label
- Your state’s laws on damages and liability
- Your attorney’s skill in presenting your case
Don’t fixate on the average. Focus on building the strongest possible case with your available medical records and documentation.
Frequently Asked Questions
How much money will I get from the gabapentin class action lawsuit?
Most individual payouts are projected between $5,000 and $250,000 depending on injury severity.
Kidney failure and wrongful death claims sit at the high end, while mild side effect claims fall at the lower end.
No settlement has been finalized yet, so these are estimates based on comparable cases.
What is the deadline to file a gabapentin lawsuit in 2026?
Deadlines vary by state, with most statutes of limitations running 2 to 3 years from injury discovery.
Some states like Florida recently shortened their window to 2 years.
Contact an attorney as soon as possible to confirm your state’s specific deadline.
Does gabapentin cause kidney damage or addiction?
Yes, medical evidence supports that gabapentin can cause both kidney damage and physical dependency.
The FDA issued a 2019 warning about respiratory risks, and multiple states have reclassified gabapentin as a controlled substance due to abuse potential.
Long-term users and those with pre-existing kidney conditions face the highest risks.
Is the gabapentin lawsuit a class action or mass tort?
Most gabapentin injury lawsuits are structured as mass tort cases, not class actions.
Mass tort allows each plaintiff’s case to be evaluated individually based on their specific injuries.
This structure typically produces higher per-person payouts than a class action.
How long will it take to get a gabapentin settlement check?
Based on similar pharmaceutical cases, settlement payments are not expected before 2029 or 2030.
The litigation is currently in the filing and pretrial phase, with bellwether trials likely in 2027 or 2028.
Filing your claim now secures your position for when distributions begin.
This gabapentin litigation is building toward something significant. The evidence of off-label marketing fraud is already established, and the injury claims are serious.
If you took gabapentin and suffered harm, gather your records now. Find an attorney handling these cases. Get your claim on file before deadlines pass.
The window is open in 2026. Use it.
